Jo Yi-jin

Hanmi Pharm's stock has corrected to historical valuation lows while the company is poised for multiple near-term catalysts: a domestic obesity drug launch in Q4, a muscle-preserving obesity treatment in phase 3, a recent landmark $1.9 trillion KRW licensing deal with only a 6% up-front refundable payment, and potential further deals. The bio sector is deeply oversold and a single positive catalyst could reverse the entire selloff.